Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Harvard Bioscience Inc Announces Details of Approved Spin-Off of Harvard Apparatus Regenerative Technology, Inc.


Wednesday, 16 Oct 2013 07:10am EDT 

Harvard Bioscience Inc announced that it has approved the spin-off of its wholly owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART. As a result of the spin-off, Harvard Bioscience will no longer own any shares of HART common stock and HART will be an independent public company. 

Company Quote

5.5
-0.05 -0.90%
10:54am EDT